TEL AVIV, Israel, May 3, 2022 /PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced that Benjamin W. Corn, MD, PhD, Chief Medical Officer, will present a company overview at the Bio€quity Europe 2022 conference taking place in Milan, Italy May 17-18, 2022 and virtually, May 23-24, 2022.
The Bio€quity Europe one-on-one partnering platform enables partners and investors to schedule meetings. If interested, please register at: https://informaconnect.com/bioequity-europe/registration-options/ or contact Michael Miller at mmiller@rxir.com.
About Lutris Pharma
Lutris Pharma is a clinical stage biopharmaceutical company focused on improving anti-cancer therapy effectiveness and quality of life for patients who are being treated with EGFR (Epidermal Growth Factor Receptor) inhibitors or with radiation, where dermal toxicity often leads to a reduction of anti-cancer therapy compliance. The company aims to provide novel topical therapies in order to mitigate these side effects. Lutris Pharma's lead asset, LUT014, a topical B-Raf Inhibitor, is a proprietary, first-in-class, small molecule currently in a phase 2 clinical trial in metastatic colorectal cancer patients with EGFR inhibitor induced acneiform lesions and a phase 1/2 study for the treatment of radiation-induced dermatitis in breast cancer patients. For more information, please visit www.lutris-pharma.com.
Contacts:
Lutris Pharma
Noa Shelach, Ph.D.
Chief Executive Officer
ir@lutris-pharma.com
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
SOURCE Lutris Pharma
